|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 914.20 DKK | +2.66% |
|
+3.28% | +30.96% |
| 11:36am | Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production | RE |
| 10:40am | NOVO NORDISK : Deutsche Bank keeps its Buy rating | ZD |
ETFs positioned on Novo Nordisk A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 208 M€ | +15.26% | - | |
| 10.45% | 4 M€ | +14.34% | ||
| 5.40% | 18 M€ | +9.16% | - | |
| 3.95% | 4 M€ | -.--% | - | |
| 3.91% | 5 M€ | +10.09% | - | |
| 3.91% | 14 M€ | +5.66% | - | |
| 3.78% | 6 M€ | -.--% | ||
| 3.09% | 12 M€ | +15.09% | - | |
| 3.02% | 6 M€ | -.--% | - | |
| 2.87% | 29 M€ | +8.37% | - | |
| 2.53% | 3,859 M€ | +18.82% | ||
| 2.53% | 469 M€ | -1.75% | ||
| 2.22% | 3 M€ | -.--% | - | |
| 1.91% | 2 M€ | -.--% | - | |
| 1.91% | 2 M€ | +9.19% | - | |
| 1.67% | 10 M€ | -3.35% | - | |
| 1.60% | 10 M€ | +6.14% | - | |
| 1.31% | 261 M€ | +10.80% | ||
| 1.30% | 51 M€ | +9.61% | ||
| 1.04% | 276 M€ | +11.40% | - | |
| 1.03% | 7 M€ | +6.26% | - | |
| 0.89% | 1,024 M€ | +8.75% | ||
| 0.79% | 284 M€ | -.--% | ||
| 0.76% | 786 M€ | -.--% | ||
| 0.76% | 23 M€ | -.--% | - | |
| 0.75% | 206 M€ | -.--% | ||
| 0.70% | 7 M€ | +0.11% | - | |
| 0.64% | 270 M€ | -.--% | - | |
| 0.64% | 209 M€ | +14.54% | - | |
| 0.64% | 458 M€ | -.--% | ||
| 0.57% | 794 M€ | +9.42% | ||
| 0.56% | 1,166 M€ | +0.26% | - |
Employees
69,260
Sector
Pharmaceuticals
Calendar
06/11/2024
- Q3 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
890.50DKK
Average target price
967.54DKK
Spread / Average Target
+8.65%
- Stock Market
- Equities
- NOVO B Stock
- ETFs Novo Nordisk A/S
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition